The Future of Molecular Testing in NSCLC
The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.
Financial Considerations with Molecular Testing for Patients With NSCLC
Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.
Receiving Molecular Testing Results for NSCLC
Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.
Integrating Molecular Testing Results into Electronic Medical Records
The panel reflects on challenges with the EMR, and the impact it has on treatment decision making for their patients with NSCLC.
Using Liquid Biopsy for Molecular Testing in NSCLC
Bhuvana Ramkumar, MD, highlights the strengths of liquid biopsy for molecular testing in NSCLC.
Types of Tissue Next-Generation Sequencing Platforms in NSCLC
Experts discuss the types of genotype panels they often use for testing patients with NSCLC, and why.
Average Turnaround Time for NSCLC Molecular Testing
Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.
Best Practices for Accurate Tissue Genotyping in NSCLC
Dr Bhuvana Ramkumar shares best practices for molecular testing in NSCLC to obtain the most accurate results.
Enhancing Communication Among the Multidisciplinary Care Team
Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.
Challenges With and Strategies for Tissue Procurement in NSCLC
Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.
Dr. Morganstein on the Mechanism of Action of Lurbinectedin in Metastatic SCLC
Neil Morganstein, MD, discusses the mechanism of action of lurbinectedin in metastatic small cell lung cancer.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512